phosphorylcholine has been researched along with Colorectal Cancer in 12 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies." | 9.15 | Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. ( Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ, 2011) |
| "34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | 9.07 | Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993) |
| "This study evaluated the biological and molecular functions of LRs in colorectal cancer (CRC) by using an LR-disrupting alkylphospholipid (APL) drug, miltefosine." | 8.02 | Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells. ( Baek, JH; Choi, JH; Kim, JH; Lee, CJ; Lee, WJ; Nam, JS; Park, S; Park, SY; Park, ZY, 2021) |
| "Our study shows that coadministration of curcumin and an orally bioactive alkylphospholipid perifosine results in a significant increase in colorectal cancer cell apoptosis and a marked inhibition of cell growth both in vitro and in vivo." | 7.78 | Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro. ( Chen, J; Chen, MB; Liu, CY; Lu, PH; Tao, GQ; Wang, LQ; Wu, XY, 2012) |
| "In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies." | 5.15 | Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. ( Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ, 2011) |
| "34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | 5.07 | Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993) |
| "This study evaluated the biological and molecular functions of LRs in colorectal cancer (CRC) by using an LR-disrupting alkylphospholipid (APL) drug, miltefosine." | 4.02 | Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells. ( Baek, JH; Choi, JH; Kim, JH; Lee, CJ; Lee, WJ; Nam, JS; Park, S; Park, SY; Park, ZY, 2021) |
| "Our study shows that coadministration of curcumin and an orally bioactive alkylphospholipid perifosine results in a significant increase in colorectal cancer cell apoptosis and a marked inhibition of cell growth both in vitro and in vivo." | 3.78 | Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro. ( Chen, J; Chen, MB; Liu, CY; Lu, PH; Tao, GQ; Wang, LQ; Wu, XY, 2012) |
| "Perifosine is a novel targeted oral Akt inhibitor currently in Phase III clinical development for treatment of colorectal cancer (CRC, in combination with capecitabine) and multiple myeloma (MM, in combination with bortezomib and dexamethasone)." | 3.78 | Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. ( Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG, 2012) |
| "The treatment of localized colorectal cancer (CRC) depends on resection of the primary tumor with adequate margins and sufficient lymph node sampling." | 1.40 | Phospholipid ether analogs for the detection of colorectal tumors. ( Albrecht, DM; Clipson, L; Deming, DA; Grudzinski, JP; Halberg, RB; Hall, LT; Leystra, AA; Lubner, SJ; Maher, ME; Matkowskyj, KA; Washington, MK; Weichert, JP, 2014) |
| "The maximum concentration of colorectal cancer patient administered oxaliplatin was 1650ng/mL." | 1.38 | A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates. ( Fujikawa, A; Furugen, A; Iseki, K; Ito, H; Kobayashi, M; Mano, N; Miyamori, K; Ogura, J; Takahashi, N; Tanaka, N; Yamada, T; Yamaguchi, H, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Park, SY | 1 |
| Kim, JH | 1 |
| Choi, JH | 1 |
| Lee, CJ | 1 |
| Lee, WJ | 1 |
| Park, S | 1 |
| Park, ZY | 1 |
| Baek, JH | 1 |
| Nam, JS | 1 |
| Park, SE | 1 |
| Chung, KS | 1 |
| Heo, SW | 1 |
| Kim, SY | 1 |
| Lee, JH | 1 |
| Hassan, AHE | 1 |
| Lee, YS | 1 |
| Lee, JY | 1 |
| Lee, KT | 1 |
| Deming, DA | 1 |
| Maher, ME | 1 |
| Leystra, AA | 1 |
| Grudzinski, JP | 1 |
| Clipson, L | 1 |
| Albrecht, DM | 1 |
| Washington, MK | 1 |
| Matkowskyj, KA | 1 |
| Hall, LT | 1 |
| Lubner, SJ | 1 |
| Weichert, JP | 1 |
| Halberg, RB | 1 |
| Bendell, JC | 1 |
| Nemunaitis, J | 1 |
| Vukelja, SJ | 1 |
| Hagenstad, C | 1 |
| Campos, LT | 1 |
| Hermann, RC | 1 |
| Sportelli, P | 1 |
| Gardner, L | 1 |
| Richards, DA | 1 |
| Chen, MB | 1 |
| Wu, XY | 1 |
| Tao, GQ | 1 |
| Liu, CY | 1 |
| Chen, J | 1 |
| Wang, LQ | 1 |
| Lu, PH | 1 |
| Richardson, PG | 1 |
| Eng, C | 1 |
| Kolesar, J | 1 |
| Hideshima, T | 1 |
| Anderson, KC | 1 |
| Ito, H | 1 |
| Yamaguchi, H | 1 |
| Fujikawa, A | 1 |
| Tanaka, N | 1 |
| Furugen, A | 1 |
| Miyamori, K | 1 |
| Takahashi, N | 1 |
| Ogura, J | 1 |
| Kobayashi, M | 1 |
| Yamada, T | 1 |
| Mano, N | 1 |
| Iseki, K | 1 |
| Beloueche-Babari, M | 1 |
| Jackson, LE | 1 |
| Al-Saffar, NM | 1 |
| Workman, P | 1 |
| Leach, MO | 1 |
| Ronen, SM | 1 |
| Planting, AS | 1 |
| Stoter, G | 2 |
| Verweij, J | 2 |
| Theischen, M | 1 |
| Bornfeld, N | 1 |
| Becher, R | 1 |
| Kellner, U | 1 |
| Wessing, A | 1 |
| Planting, A | 1 |
| van der Burg, M | 1 |
| Berger, MR | 1 |
| Richter, H | 1 |
| Seelig, MH | 1 |
| Eibl, H | 1 |
| Schmähl, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients[NCT00398879] | Phase 2 | 381 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
4 trials available for phosphorylcholine and Colorectal Cancer
| Article | Year |
|---|---|
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2011 |
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Leuk | 1993 |
Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Electrooculography; Electroretinography | 1993 |
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colore | 1992 |
8 other studies available for phosphorylcholine and Colorectal Cancer
| Article | Year |
|---|---|
Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Me | 2021 |
Therapeutic role of 2-stearoxyphenethyl phosphocholine targeting microtubule dynamics and Wnt/β-catenin/EMT signaling in human colorectal cancer cells.
Topics: beta Catenin; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal N | 2023 |
Phospholipid ether analogs for the detection of colorectal tumors.
Topics: Adenocarcinoma; Animals; Colorectal Neoplasms; Female; Humans; Indoles; Intestinal Neoplasms; Iodobe | 2014 |
Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caco-2 Cells; Cell Death; Cell L | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Ca | 2012 |
A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates.
Topics: Acetonitriles; Antineoplastic Agents; Chromatography, Liquid; Colorectal Neoplasms; Humans; Hydropho | 2012 |
Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition.
Topics: Biomarkers, Tumor; Breast Neoplasms; Butadienes; Cell Line, Tumor; Colorectal Neoplasms; Enzyme Inhi | 2005 |
New cytostatics--more activity and less toxicity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colorectal Neoplasms; Female; Male; Mammary Neoplasm | 1990 |